Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview

彭布罗利珠单抗 阿替唑单抗 无容量 医学 易普利姆玛 杜瓦卢马布 肿瘤科 肺癌 成本效益 内科学 免疫疗法 癌症 风险分析(工程)
作者
Changjin Wu,Wentan Li,Hongyu Tao,Xiyan Zhang,Xin Yu,Ruomeng Song,Kaige Wang,Ling Zuo,Yuanyi Cai,Huazhang Wu,Wen Hui
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:193: 104195-104195 被引量:13
标识
DOI:10.1016/j.critrevonc.2023.104195
摘要

Immunotherapies can substantially improve treatment efficacy, despite their high cost. A comprehensive overview of the cost-effectiveness analysis (CEA) of immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer based on different tumor proportion scores (TPSs) was conducted. PubMed, Embase, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and NHS Economic Evaluation databases were searched from their inception until August 24, 2022. Data relevant to the CEA results were recorded, and quality assessments conducted based on the Quality of Health Economic Studies (QHES) process. Fifty-one original studies from seven countries were included. The mean QHES score was 77.0 (range: 53–95). Twenty-seven studies were classified as high-quality, and the rest as fair quality. Pembrolizumab, nivolumab, ipilimumab, atezolizumab, camrelizumab, cemiplimab, sintilimab, tislelizumab, and durvalumab were identified using three TPS categories. While nivolumab plus ipilimumab and pembrolizumab plus chemotherapy were unlikely to be cost-effective in China, the results for the US were uncertain. Atezolizumab combinations were not cost-effective in China or the US, and tislelizumab and sintilimab were cost-effective in China. For TPSs ≥ 50%, the pembrolizumab monotherapy could be cost-effective in some developed countries. Cemiplimab was more cost-effective than chemotherapy, pembrolizumab, and atezolizumab in the US. For TPSs ≥ 1%, the cost-effectiveness of pembrolizumab was controversial due to the different willingness-to-pay thresholds. None of the atezolizumab combination regimens were found to be cost-effective in any perspective of evaluations. Camrelizumab, tislelizumab, and sintilimab have lower ICERs compared to atezolizumab, pembrolizumab, and nivolumab in China. Cemiplimab may be a more affordable alternative to pembrolizumab or atezolizumab. However, it remains unclear which ICIs are the best choices for each country. Future CEAs are required to select comprehensive regimens alongside randomized trials and real-world studies to help verify the economics of ICIs in specific decision-making settings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈哈发布了新的文献求助10
刚刚
刚刚
hello完成签到,获得积分20
1秒前
小二郎的应助被ygy采纳,获得10
1秒前
2秒前
bertharen完成签到,获得积分20
2秒前
堪冷之完成签到,获得积分10
2秒前
求文献完成签到 ,获得积分10
2秒前
搞怪谷蓝发布了新的文献求助50
2秒前
3秒前
3秒前
Gulu_完成签到 ,获得积分10
3秒前
小画发布了新的文献求助10
4秒前
杨汐菥发布了新的文献求助10
4秒前
科研通AI6.3的应助被王晨采纳,获得10
5秒前
5秒前
MichaelQiang的应助被健壮的涑采纳,获得30
6秒前
6秒前
6秒前
小蘑菇的应助被北辰小狼采纳,获得10
6秒前
6秒前
towerman完成签到,获得积分10
7秒前
qqq完成签到,获得积分10
7秒前
烟花的应助被Fly采纳,获得10
8秒前
七月的应助被ercha采纳,获得10
9秒前
酷酷酷发布了新的文献求助10
9秒前
archer发布了新的文献求助10
9秒前
小碗发布了新的文献求助10
10秒前
充电宝的应助被你说什么采纳,获得10
10秒前
11秒前
12秒前
12秒前
Firsterchao发布了新的文献求助30
12秒前
NexusExplorer的应助被zhangzhuopu采纳,获得10
12秒前
yanhong发布了新的文献求助10
12秒前
愤青发布了新的文献求助10
13秒前
活泼忆曼完成签到,获得积分10
13秒前
13秒前
拉唑完成签到,获得积分10
13秒前
辰辰发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188088
求助须知:如何正确求助?哪些是违规求助? 9575942
关于积分的说明 21844291
捐赠科研通 7785857
什么是DOI,文献DOI怎么找? 3435158
关于科研通互助平台的介绍 2559529
邀请新用户注册赠送积分活动 2482065